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Abstract
Background: Preterm birth is a major cause of neonatal mortality, especially in low and middle income countries.
Antenatal corticosteroid therapy for foetal maturation could have a significant impact and therefore is often
referred to as an important strategy to reduce neonatal mortality. A recently conducted large multinational trial
showed that antenatal corticosteroids can have adverse effects in low income countries, but this is likely to depend
on the specific setting. In our hospital preterm birth is only recognized in patients with severe maternal disease,
due to physician-initiated delivery. Spontaneous preterm births are rarely seen in the hospital and often take place
in the community or while on the road to a health facility.
Objective: To investigate the effects of antenatal corticosteroid therapy in a rural hospital in Tanzania.
Methods: A secondary analysis of a retrospective medical records study of women with severe pre-eclampsia and
eclampsia performed in Ndala Hospital between July 2011 and December 2012. We used data on gestational age,
birth weight, Apgar score, time between admission and birth, use of corticosteroids and maternal and foetal
survival. Ethical clearance was obtained from the directorate of research and publications of the University of
Dodoma (ref. UDOM/DRP/346).
Results: Thirty-six women with forty live foetuses were analysed. Twelve women (13 neonates) were given
corticosteroids and could be compared to 24 women (27 neonates) who did not get corticosteroids. The incidence
of fresh stillbirths (antenatal death) was 20 %. The 13 neonates who received corticosteroids had significantly
smaller birth weight, longer interval between admission and delivery and poorer outcomes (stillbirth and neonatal
death). An analysis of 24 neonates with a birth weight between 1.5 and 2.5 kg showed a trend toward better
outcome in neonates who did not receive antenatal corticosteroid therapy.
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Conclusion: Small retrospective studies as these have a low level of evidence, but this study helped to gain more
knowledge of local conditions affecting the effectiveness of antenatal corticosteroid therapy in our setting of a small rural
hospital. Reliability of estimating gestational age, epidemiology of preterm birth, exposure to infections, foetal monitoring
and quality of neonatal care are likely to influence the effect of antenatal corticosteroid therapy. Further larger prospective
studies should be conducted to determine the exact preconditions of antenatal corticosteroid therapy in low-income
countries. Until that time, the WHO precautions seem reasonable and audits and small observational studies like ours can
help in assessing whether a specific hospital is suited for antenatal corticosteroid therapy.
Keywords: Low-income countries, Preterm birth, Glucocorticoids, Antenatal corticosteroid therapy, Tanzania
Abbrevations: ACT, Antenatal corticosteroid therapy; CS, Caesarean section; CTG, Cardiotocography; GA, Gestational age;
IM, Intra-muscular; LIC, Low-income countries; SVD, Spontaneous vaginal delivery; TB, Tuberculosis; WHO, World Health
Organization
Background
Almost 10 % of births worldwide are preterm and the
incidence increases to 20 % in parts of Africa [1]. Caus-
ing one million neonatal deaths each year, most of which
occur in low- and middle-income countries, preterm
birth is a major cause of neonatal mortality [2]. The rate
of preterm birth is not expected to fall and might even
increase, partly because of lack of preventive measures
and partly because of physician-initiated deliveries for
various conditions [3]. Antenatal corticosteroid therapy
(ACT) for foetal maturation could have a significant im-
pact on neonatal survival [4, 5].
Corticosteroids trigger the maturational process lead-
ing to the release of surfactant into the alveoli of the
foetal lung, preventing respiratory distress syndrome [6].
ACT for foetal maturation has been undisputed since
the publication by Liggins and Howie in 1972 [7], al-
though long-term health effects have been less well stud-
ied [8]. In the most recent Cochrane systematic review
of 18 trials the effect there was a 34 % reduction of re-
spiratory distress syndrome, a 46 % reduction of intra-
ventricular haemorrhage and a 31 % reduction in
neonatal mortality [9]. The use of ACT is incorporated
in many guidelines [9–11]. Recently a study has shown
positive effects for late preterm birth as well [12].
A review in middle-income countries (Brazil, Jordan,
Tunesia and South Africa) showed a mortality reduction
of 53 % [13]. The authors remark that the effect in low-
income countries (LIC) might be even larger due to lack
of neonatal health care facilities and limited access to ex-
pensive interventions such as surfactant therapy. Hence,
ACT is often referred to as an important strategy to re-
duce neonatal mortality in LIC [5, 14–20]. In Tanzania
ACT has been listed as a cost effective measure in the
2008 national road map strategic plan to reduce new-
born and child deaths [21, 22].
However, some doubts were voiced about ACT in LIC
[23], which were reinforced when in 2015 a LIC-ACT trial
was published in The Lancet by Althabe et al. [24]. This large
trial investigated ACT implementation versus regular care in
100,000 women in six countries (Argentina, Guatalamala,
India, Kenya, Pakistan, Zimbabwe). This population based
study did not show a positive effect in the preterm infants
group, even though nearly half of them received ACT. In this
study, an increase in overall perinatal and neonatal mortality
in the whole group was shown [24, 25], probably due to dele-
terious effects of overtreatment by ACT in patients who were
not preterm (84 %). Also there was an increase in suspected
maternal infection and an increased maternal mortality ratio.
This trial was conducted mostly at community level with
only 13 % of women identified for ACT in a hospital.
In response to these findings, the World Health
Organization (WHO) has recommended the following
conditions to be met before ACT administration for
women at risk for preterm birth between 24 and
34 weeks of gestation: Gestational age (GA) can be ac-
curately assessed, preterm birth is imminent, there is no
evidence of infection and adequate childbirth care and
care for the preterm neonate are available [26, 27].
We were interested to examine the situation in our local
hospital. To assess the effects of ACT in a hospital in a
low-resource setting in rural Africa, we analysed data from
a subset of women included in a previous retrospective
study conducted in women with severe pre-eclampsia and
eclampsia. Even though spontaneous preterm labour is an
indication for ACT in the national and hospital protocols,
in our hospital hypertensive disorders in pregnancy are
the most important indications for ACT.
Methods
Setting
This study was done at Ndala Hospital, a private Cath-
olic hospital, situated in the Tabora region, in a rural
part of Western Tanzania. It serves a catchment area of
approximately 200,000 people. Annually, approximately
2,200 women give birth in the hospital. Comprehensive
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emergency obstetric care is available. There are virtually
no possibilities for urgent referral to the regional hos-
pital. Monitoring of foetal wellbeing is done by a foetal
heart doppler once daily with admitted patients and
more regularly during labour (4 hourly during 1st stage
of labour, every 15 min during 2nd stage). Cardiotoco-
graphy (CTG) is not available. Obstetric ultrasound is
available, but is used for specific indications only and
not routinely for estimation of GA or foetal biometry.
Because of late booking 1st and early 2nd trimester
ultrasound is rarely done. GA is calculated using mater-
nal history of last menstrual period or, if unknown, by
measuring fundal height. In case there is a discrepancy
between maternal history and fundal height, the clinician
decides which GA is most likely, sometimes helped by
information from earlier visits to the antenatal clinic.
Ultrasound measurement of foetal biometry is not used
in these patients because of limited resources and insuf-
ficiently trained healthcare workers. Neonatal resuscita-
tion is done by mask and balloon only; there are no
possibilities for assisted ventilation. Premature neonates
are admitted with their mothers in the premature room
for frequent cup feeding and Kangaroo Mother Care.
Participants
This is a secondary analysis of a retrospective medical
records study of women with severe pre-eclampsia and
eclampsia performed in Ndala Hospital between July
2011 and December 2012 [28]. During this period 3398
women gave birth in the hospital. Eighty-one patients
(90 neonates) were included in the original study (Fig. 1).
In the present study, we included a subset of neonates
from 36 women without contractions (40 live foetuses).
The patients were identified by the first author (RM) or
one of the attending doctors. Medical records were
searched immediately following discharge or death and a
standard case record form was filled in by the dischar-
ging doctor and cross-checked. In case of discrepancies
or missing data, the medical records were checked again.
For this analysis about the effect of ACT, we used data
on GA, birth weight, Apgar score, time between admis-
sion and birth, use of corticosteroids and maternal and
foetal survival. We performed a subgroup analysis of ne-
onates with a birth weight between 1.5 and 2.5 kg, to try
to compensate for indication bias.
The use of ACT was considered in cases of severe pre-
eclampsia in mothers without contractions and sus-
pected prematurity (GA suspected < 34 weeks or <
2.5 kg) with a live baby. The decision to start ACT was
based on the estimated GA, maternal condition and the
preferences of the patient or her relatives. In case of
eclampsia, although the hospital protocol advises prompt
induction of labour after stabilizing the maternal condi-
tion, this was sometimes delayed and ACT was given
outside of the protocol.. Overtreatment was defined as
ACT given when there was no low birth weight, which
means that the weight was over 2.5 kg [29]. Dexametha-
sone was given (8 mg intra-muscular (IM)) and repeated
once after 24 h. The course was considered completed
48 h after the first dose.
Statistical analysis
Data management was done using Microsoft Excel®, stat-
istical analysis was done with Epi Info®. P-values were
calculated with Fisher-Exact test, T-test and Mann-
Whitney /Wilcoxon test, whether appropriate.
Results
Thirty-six women who were not in labour on admission
carried 40 live foetuses. Twelve women (13 neonates)
were given ACT and could be compared to 24 women
(27 neonates) who did not get ACT. Sixty-seven percent
of women (24/36) had eclampsia, while 33 % (12/36)
had severe pre-eclampsia and this was similar in women
who had received ACT and who had not. All but one
woman received magnesiumsulphate. Of all these
women all data could be retrieved. One woman received
an incomplete dose of ACT: she gave birth to a baby of
1.3 kg, which died after delivery. Data of this patient
were analysed in the group of women receiving cortico-
steroids (intention to treat analysis).
The overall neonatal survival was 68 % (27/40), with a
mean birth weight of 2.2 kg. The incidence of fresh still-
births (antenatal death) was 20 %. The thirteen neonates
who received ACT had significantly smaller birth weight,
longer interval between admission and delivery and
poorer outcomes (see Table 1). Overtreatment (ACT
given to foetuses >2.5 kg) occurred in 38 % of ACT
courses. One maternal death occurred (bleeding compli-
cation of Caesarean section) in a woman who had not
Fig. 1 Patient selection (number of foetuses*)
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received ACT. Induction with misoprostol was done in
twenty-two women (25/27 foetuses, 93 %) who did not
receive ACT and in eight women (8/13 foetuses, 62 %)
who received ACT.
All four neonates with a birth weight < 1.5 kg died be-
fore or during birth (all received corticosteroids). Of the
twelve children above 2.5 kg ten survived (83 %). None
of the two children that died (one antenatal, one postna-
tal) had suspected respiratory distress syndrome (RDS).
Of the neonates who received ACT, 4 (4/13 = 31 %) had
a birth weight < 1.5 kg and 1 (1/13 = 8 %) a birth weight
above 2.5 kg.
This subgroup of neonates with a birth weight be-
tween 1.5 and 2.5 kg consists of eight neonates who
received ACT and sixteen who did not. In both
groups the birth weights and reported GA were not
significantly different. In the group who did not re-
ceive ACT, the admission to delivery interval was sig-
nificantly shorter and neonatal outcome better (not
significant) (Table 2). Thirty-eight percent (5/13) of
women receiving ACT carried foetuses of less than
1.5 kg or more than 2.5 kg.
Discussion
In our small group of 40 neonates in women with severe
hypertensive disorder no benefit of ACT could be dem-
onstrated. An analysis of 24 neonates with a birth weight
between 1.5 and 2.5 kg showed a trend toward better
outcome in neonates who did not receive ACT, however
the results of this small retrospective study must be
regarded with caution.
Overtreatment was defined as ACT given when the
birth weight was over 2.5 kg. This is the 50th weight
percentile at 35 weeks of GA. A small positive effect for
late preterm birth has been established recently, but has
not been incorporated in guidelines for LIC [9, 12, 30].
The cut-off birthweight in the LIC-ACT trial was calcu-
lated as 2000–2500 g depending on the country [24].
Study limitations
Our study has several limitations.
Firstly, because of the retrospective setup, both groups
had different characteristics. There is risk for indication
bias as the reasons for starting ACT or initiating prompt
delivery were not well described. For example, the
Table 1 Characteristics of 40 neonates of women not in labour
Number of neonates (womena) Received ACT: 13 (1 incomplete) (12a) Not received ACT: 27 (24a) P-value
Pre-eclampsia/eclampsia
Eclampsia 9 (8a) (69 %) 17 (16a) (63 %) 1 (Fisher)
Pre-eclampsia 4 (31 %) 10 (8a) (37 %)
Maternal outcome
Mother died 0 (0 %) 1 (3.7 %) 1 (Fisher)
Mother survived 13 (11a) (100 %) 26 (23a) (96 %)
Multiple gestation
Twins 2 (1a) (15 %) 6 (3a) (22 %) 1 (Fisher)
Singleton 11 (85 %) 21 (78 %)
Median self-reported gestational age
(months, interquartile-range)
7 (7–8) 8 (8–9) <0.01 (MW/Wilcoxon)
Average weight (range) 1.8 kg (0.8–3.2 kg) 2.4 kg (1.5–4 kg) 0,03 (T-test)
Median between admission-delivery
(hours, interquartile-range)
147 (72–200) 42 (17–72) <0.01 (MW/Wilcoxon)
Perinatal outcome
Alive child at discharge 5 (38 %) 22 (81 %) <0.01 (Fisher)
Perinatal death 8 (62 %) 4 (19 %)
Intrauterine death 5 (38 %) 3 (11 %)
Labour
Spontaneous labour & delivery 3 (23 %) 2 (7 %) 0.3 (Fisher)
Primary SC 2 (1a) (15 %) 0 (0 %)
Induction, SVD 6 21 (18a)
Failed induction, secondary SC 1
Successful induction, secondary SC when in labour 1 3
Induction, ventouse delivery 1
atwins: number of women, calculations are with foetuses
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decision to withhold ACT could have been based upon
the estimation that either the baby would be too small
or too large to benefit from ACT. The hospital protocol
advises direct delivery without ACT in case of eclampsia,
yet two-thirds of women had eclampsia and were treated
outside of the protocol. This is because when the mater-
nal condition improved after initial treatment with mag-
nesiumsulphate the mother and relatives often refused
preterm delivery or needed time to consider this, and
ACT was given in the mean time.
Secondly, since GA (and estimated weight) was never
exactly known, the inclusion for ACT was not done ac-
cording to the correct GA (26–34 weeks), which can
have led to underestimation of the positive effect of
foetal maturation in case of small for gestational age in-
fants. Our results underline the fact that medical deci-
sion making is difficult without known GA and show the
advantage of early booking ultrasound to determine the
exact GA. However in many LIC this is not realistic and
in clinical practice, as well as studies, the use of proxies
and clinical judgement is required [24].
We have tried to correct for both these limitations in
Table 2, analyzing subgroups with comparable birth-
weight (as a proxy for GA), however this analysis could
have included small for gestational age (growth re-
stricted) newborns as well and although the proportion
of women with severe disease (eclampsia) is the same in
both groups, the median self-reported GA and birth
weight are slightly lower (non-significant) in the group
that received ACT. The groups were too small to per-
form regression analysis for this confounder and we
could not exclude other possible reasons for bias.
A third limitation is the setting: the study was not done
in a general population of women with clinical signs of
preterm birth, but done in women with indication for in-
duction of labour because of severe pre-eclampsia and
eclampsia. However, this is the clinical practice in our set-
ting in which hypertensive disorder in pregnancy is the
only circumstance in which ACT is given. In the study
period there were no women without pre-eclampsia or
eclampsia who received ACT, either because they did not
arrive in time in the hospital (born before arrival or
arrived in second stage of labour) or were not adequately
identified on admission [31]. This limitation means the re-
sults cannot be generalized to other settings, but represent
daily practice in our hospital.
Lastly, the dexamethasone schedule of 2 times 8 mg
dexamethasone is a lower dose than the advised dosage of
4 times 6 mg IM in 48 h and might have been less effective.
Several authors have given explanations for increased
risk and lower effectiveness of ACT in low-income
countries [3, 19, 23, 25, 32]. We want to discuss several
aspects of using ACT in low resource settings, using the
findings of our study.
Causes of inappropriate administration of ACT
 Uncertain GA: in a setting of late booking without
availability of (early) ultrasound it is difficult to
identify women who can benefit from ACT, since it
is difficult to estimate foetal body weight and not
possible to identify intra-uterine growth restriction.
In our study there was a considerable overtreatment
of 38 % of women who were not eligible to receive
ACT. In the LIC-ACT trial of the 13 % of women
receiving ACT, only 16 % delivered a preterm infant
(in both studies using birth weight as a proxy for
GA). The difference in overtreatment can be
explained because in our group all women receiving
ACT delivered shortly after (because of induced
preterm birth), but the GA was uncertain. In the
LIC-ACT trial, not only the GA was uncertain, but
also if preterm delivery was really imminent. The
elevated risk in overall newborn mortality, from 23.9
to 27.4 per 1000 and even more significant in
African sites of the study, has been attributed mainly
to the inappropriate administration of ACT to
mothers who gave birth to neonates who were not
premature [32–34]. Although positive effects have
been shown in the late-preterm period, these are
much smaller [12]. Not only will this dilute any
effects of ACT, but women and babies are also
exposed to the risk of corticosteroids without the
benefits.
Table 2 characteristics of 24 neonates of women not in labour between 1.5 and 2.5 kg
Number of neonates (womena) Received ACT: 8 (7a) Not received ACT: 16 (13a) P-value
Median self-reported gestational age (months, interquartile-range) 8 (7–8) 8 (8–9) 0.31 (T-test)
Average weight (range) 2.1 kg (1.5–2.4 kg) 1.9 kg (1.5–2.5 kg) 0.50 (MW/Wilcoxon)
Median between admission-delivery (hours, interquartile-range) 144 (96–250) 22 (16–76) <0.01 (MW/Wilcoxon)
Perinatal outcome
Alive child at discharge 4 (50 %) 13 (81 %) 0.17 (Fisher)
Perinatal death 4 (50 %) 3 (19 %)
Intra-uterine death 2 (25 %) 1 (6,3 %)
atwins: number of women, calculations are with foetuses
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 Difficulty in identifying women with imminent
preterm birth: although preterm labour is an
important indication for ACT in high income
settings, in many hospitals in low resource settings
ACT is never used for this. Few women present
with preterm labour and even if they do, often
prematurity is not suspected since GA is not known.
When preterm labour is suspected, arrival in the
hospital can be too late to start tocolytics. There
might be lack of awareness by healthcare workers
and mothers. After health-provider training preterm
labour was the most common indication (77 %) for
ACT in the LIC-ACT trial and 70 % of women com-
pleted the course [24]. Ultimately more than half of
women delivered at term, indicating that it is diffi-
cult to diagnose imminent preterm birth [35].
Preterm rupture of membranes before 32 weeks GA
is also a recognized indication for ACT [9, 36, 37].
These patients as well often do not seek medical
attention in the setting of our study area and in the
few cases that are admitted in our hospital, ACT is
not given because of the fear of sepsis.
In our hospital ACT is only given to women with
severe maternal disease requiring termination of
pregnancy, almost always severe hypertensive
disorder. Although in high-income countries evi-
dence of the benefits for this treatment regime is
clear [9], a different analysis has to be made in LIC,
since the risks are different. ACT requires postpon-
ing delivery for 48 h, while women with severe dis-
eases have a serious risk of severe maternal
morbidity or even maternal mortality and cannot al-
ways be monitored and treated adequately. Many
women with severe hypertensive disorder in a low-
resource setting already report late at health institu-
tions as a result of delay caused by late recognition
of dangers signs, challenges in the decision-making
process to go to the hospital and/or transport prob-
lems [28].
Increased risk of corticosteroids
 Risk of infections: corticosteroids increase
susceptibility to infection and decrease immune
function [3]. In LIC the infectious disease burden is
higher and the level of antisepsis lower. Sepsis is a
main cause of foetal and maternal mortality, so the
effect of administering ACT is potentially dangerous.
Corticosteroids are contra-indicated in patients
with chronic infections [36]. HIV, malaria and tu-
berculosis (TB) are more common in LIC. The
first can easily be excluded before administering
ACT, but Tanzania has a high burden of tubercu-
losis with a prevalence of 176/100,000 in 2012
[38], with many patients being asymptomatic and
unaware of their illness. In 2012, 138 patients
were registered at the TB clinic and 2798 at the
HIV Care and Treatment clinic of our hospital
[39].
Limited possibility for adequate preterm birth care and
postnatal care
 Diagnosing and monitoring foetal and maternal
condition: ACT is contra-indicated if there are signs
of chorio-amnionitis [36]. Our study setting is
characterised by an understaffed and overburdened
labour ward, with limited possibilities of clinical
monitoring like temperature and no CTG or
laboratory markers such as C-reactive protein. This
leads to inadequate identification of infection. Aside
from infection, the foetus is also at a higher risk of
intra-uterine death because of the mothers condition
(e.g., insufficient placental function in eclampsia) or
birth asphyxia. Without the possibility of foetal
monitoring we found a high antenatal and perinatal
mortality of 20 %. Keeping the foetus in this
dangerous environment without the ability to check
the foetal condition can lead to undetected foetal
distress and eventually death.
 □ Neonatal care: causes of neonatal mortality of
preterm infants in resource-limited settings are
hypothermia, hypoglycaemia, birth asphyxia, infec-
tion and respiratory issues. To address only the lat-
ter cause when the others cannot be well managed
has been called useless [40].
Our small observational study supports the recent
findings that ACT is not always beneficial in LIC. Be-
cause of its heterogeneity the LIC-ACT trial is not ap-
plicable to all hospitals in LIC. Our study is limited by
bias and small numbers, however it provides insight in
the practice in a rural hospital. The WHO has recom-
mended accurate assessment of GA, prediction of
imminent preterm birth, evidence of no infection and
adequate childbirth care and care for the preterm neo-
nate to be present before ACT is implemented [26, 27].
Our data support these general recommendations. Fur-
ther larger prospective studies can determine the exact
preconditions of ACT in LIC. Until that time, audits and
small observational studies like ours can help in asses-
sing whether a specific hospital is suited for ACT.
Conclusion
In forty neonates born prematurely due to mothers with
severe pre-eclampsia and eclampsia no benefit of ACT
could be demonstrated. An analysis of 24 neonates with
a birth weight between 1.5 and 2.5 kg showed a trend
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toward better outcome in neonates who did not receive
ACT. These results are in line with recent findings that
ACT is not always beneficial. Small retrospective studies
as these have a low level of evidence, but this study
helped to gain more knowledge of local conditions af-
fecting the effectiveness of ACT in our setting of a small
rural hospital. Reliability of GA estimation, epidemiology
of preterm birth, exposure to infections, foetal monitor-
ing and quality of neonatal care are likely to influence
the effect of ACT, but it is unclear what exact precondi-
tions are required for ACT to be effective and safe. Fur-
ther larger prospective studies should be conducted to
determine the exact preconditions of ACT in LIC. Until
that time, the WHO precautions seem reasonable and
audits and small observational studies like ours can help
in assessing whether a specific hospital is suited for
ACT.
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